GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Price-to-Funds-From-Operations

ACUT (Accustem Sciences) Price-to-Funds-From-Operations : (As of Apr. 22, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Accustem Sciences Business Description

Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.